Two drugs better than one in relapsed indolent lymphoma
The addition of lenalidomide to rituximab extends progression-free survival by two years, US study shows
5th April 2019
Patients with relapsed or refractory indolent non-Hodgkin lymphoma enjoy two years of progression-free survival when lenalidomide is added to routine rituximab teatment, a study shows.